Erick Bulawa, MD
Internal Medicine · Greeneville, TNNPI 1326020199
Payments from drug & device makers
Across 165 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$754
- Lilly USA, LLC$277
- Amgen$164
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$155
- AstraZeneca$150
- Intra-sana Laboratories$135
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,699100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $754 |
| Lilly USA, LLC | 18 | $277 |
| Amgen | 11 | $164 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $155 |
| AstraZeneca | 10 | $150 |
| Intra-sana Laboratories | 8 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $112 |
| AbbVie(2 entities) | 5 | $104 |
| Intuitive Surgical | 1 | $95 |
| Rhythm Pharmaceuticals, Inc. | 6 | $94 |
| MDD US Operations, LLC | 1 | $85 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $70 |
| Pfizer | 4 | $69 |
| Supernus Pharmaceuticals, Inc. | 3 | $57 |
| GSK | 4 | $53 |
| Astellas Pharma US Inc | 2 | $43 |
| Shire North American Group Inc | 3 | $41 |
| Novartis | 3 | $40 |
| Eisai Inc. | 2 | $27 |
| Corcept Therapeutics | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| Bayer | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
How this compares
$2,710 in reported general payments places this provider in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 230 | $240,702 |
| EliquisApixaban | 76 | $65,955 |
| JardianceEmpagliflozin | 76 | $59,770 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $50,354 |
| TrulicityDulaglutide | 30 | $41,493 |
| OzempicSemaglutide | 36 | $35,986 |
| LinzessLinaclotide | 48 | $30,682 |
| JanuviaSitagliptin Phosphate | 24 | $26,207 |
| XareltoRivaroxaban | 13 | $15,407 |
| FarxigaDapagliflozin Propanediol | 15 | $14,677 |
| QuliptaAtogepant | 11 | $13,989 |
| Repatha SyringeEvolocumab | 12 | $11,786 |
| VyvanseLisdexamfetamine Dimesylate | 25 | $9,669 |
| Repatha SureclickEvolocumab | 12 | $7,382 |
| Dexlansoprazole DrDexlansoprazole | 29 | $6,149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $277 | $283,954272 claims |
| PfizerEliquis | $69 | $65,95576 claims |
| Boehringer IngelheimJardiance | $12 | $59,77076 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $53 | $55,11285 claims |
| AbbVieLinzess, Qulipta | $104 | $44,67259 claims |
| Novo NordiskOzempic | $754 | $35,98636 claims |
| AstraZenecaFarxiga | $150 | $14,67715 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $112 | $9,66925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Greeneville
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.